Cuba begins Renal cancer drug trial
Key Points(5)
- <strong>By Kayla Higgs</strong> A clinical trial with Heberferon, one of the leading lines of Cuban biotechnology, will begin this year in Cuba in about 300 patients with renal carcinoma.
- Dr Iraldo Bello, is the expert who developed the product at the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym).
- According to Caribbean News Now, Bello said that this formulation, a synergistic combination of recombinant human alpha-2b and gamma interferon, has been applied with good results against basal cell carcinoma, the most frequent skin cancer.
- Bello added that this year they will also conduct a clinical trial with Heberferon in patients with malignant brain tumors.
- Preclinical studies and other pilot research in humans show that the results with this product, unique of its kind in the world, can be very promising in these two indications, said the expert.
By Kayla Higgs
A clinical trial with Heberferon, one of the leading lines of Cuban biotechnology, will begin this year in Cuba in about 300 patients with renal carcinoma.
Dr Iraldo Bello, is the expert who developed the product at the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym).
According to Caribbean News Now, Bello said that this formulation, a synergistic combination of recombinant human alpha-2b and gamma interferon, has been applied with good results against basal cell carcinoma, the most frequent skin cancer.
Bello added that this year they will also conduct a clinical trial with Heberferon in patients with malignant brain tumors. Preclinical studies and other pilot research in humans show that the results with this product, unique of its kind in the world, can be very promising in these two indications, said the expert.
Bello has spent over 20 years in the research of this product, which has raised interest in several countries.
The CIGB and the National Cancer Control Group develop workshops in which oncologists, pathologists and other specialists participate to educate physicians about the use of the drug, which has already been applied to 800 Cuban patients with basal cell carcinoma.
